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Abstract
Background
The incidence rate of breast cancer is increasing and has become the most common cancer
in Vietnamese women while the survival rate is lower than that of developed countries. Early
detection to improve breast cancer survival as well as reducing risk factors remains the cor-
nerstone of breast cancer control according to the World Health Organization (WHO). This
study aims to evaluate the costs and outcomes of introducing a mammography screening
program for Vietnamese women aged 45–64 years, compared to the current situation of no
screening.
Methods
Decision analytical modeling using Markov chain analysis was used to estimate costs and
health outcomes over a lifetime horizon. Model inputs were derived from published literature
and the results were reported as incremental cost-effectiveness ratios (ICERs) and/or incre-
mental net monetary benefits (INMBs). One-way sensitivity analyses and probabilistic sen-
sitivity analyses were performed to assess parameter uncertainty.
Results
The ICER per life year gained of the first round of mammography screening was US
$3647.06 and US$4405.44 for women aged 50–54 years and 55–59 years, respectively. In
probabilistic sensitivity analyses, mammography screening in the 50–54 age group and the
55–59 age group were cost-effective in 100% of cases at a threshold of three times the Viet-
namese Gross Domestic Product (GDP) i.e., US$6332.70. However, less than 50% of the
cases in the 60–64 age group and 0% of the cases in the 45–49 age group were cost effec-
tive at the WHO threshold. The ICERs were sensitive to the discount rate, mammography
sensitivity, and transition probability from remission to distant recurrence in stage II for all
age groups.
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Conclusion
From the healthcare payer viewpoint, offering the first round of mammography screening to
Vietnamese women aged 50–59 years should be considered, with the given threshold of
three times the Vietnamese GDP per capita.
Introduction
Globally, breast cancer is the most prevalent cancer in women. In terms of mortality, breast
cancer becomes the leading cause of cancer related death in women in developing countries
and the second leading cause in developed countries [1–3]. Approximately 1.67 million new
breast cancer cases were diagnosed (25% of all cancers) and 522,000 deaths from breast cancer
occurred in 2012 all over the world [4]. Although breast cancer is thought to be a common
female disease in high-income countries, nearly 50% of breast cancer cases and 58% of deaths
due to breast cancer occur in low- and middle-income countries where the majority of women
were diagnosed at the late stages [5]. Breast cancer is also the most common cancer among
women in Vietnam. The incidence rate rose from 13.8 per 100,000 Vietnamese women (in
2000) to 28.1 per 100,000 Vietnamese women (in 2010). According to Duc NB, 12,533 women
with breast cancer were diagnosed in 2010 [6]. Potentially explanatory factors for the rising
rate of breast cancer in Vietnamese women were: the fall in fertility rate, the increase in over-
weight women, and the improved healthcare system (i.e., the increased availability of diagnos-
tic tests) [7]. The peak age group of breast cancer was 50–54 years in Vietnamese women.
Breast cancer is the third leading cause of death from cancer; only liver cancer and lung cancer
account for more cancer deaths in Vietnamese women [8].
Early detection can improve breast cancer outcomes and the survival of breast cancer
patients. The highest proportion of breast cancer patients in low and middle-income countries,
including Vietnam, are diagnosed at the late stages which makes the treatment more difficult
and costly [7]. Therefore, breast cancer screening in the general population could potentially
reduce both the health burden and the economic burden of breast cancer. Although there are
currently some breast cancer screening approaches, only mammography screening has been
proven to reduce breast cancer mortality by early detection in population-based programs [2].
National mammography screening programs have been widely implemented including in
Europe, North America, and Australia and the cost-effectiveness of these schemes has been
published [9–12]. An estimated cost per life year gained of US$27,000 was found in the US
[13] and US$19,919 in Australia [14]. In Asian countries, the cost per life year gained had a
large range from US$19,257 (India) [15] and US$29,964 (South Korea) [16] up to US$64,400
(China) [17]. However, the guidelines of optimal screening policies (start age, end age, and
interval screening) differ between countries. The American Cancer Society recommends that
annual mammography screening for women begins at age 45 [18]. The Department of Health
of the Australian Government recommends women aged between 50 and 74 years for biennial
mammography screening. Factors such as age, breast tissue density, and screening interval,
affect the sensitivity and specificity of mammography screening. Some Asian countries, such
as South Korea, Japan, and Singapore, have initiated population-based screening programs. In
South Korea, women are being screened with mammography every two years, starting at age
40 [19]. The Ministry of Health of Singapore recommends that biennial mammography
screening should be implemented for women between 50–69 years [20]. According to Chisato
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Hamashima et al., Japanese women between 40–74 years of age should be screened by mam-
mography without clinical breast examination for population-based screening [21].
National mammography screening is presently not performed in Vietnam; there is only pri-
vate screening (patients pay the screening fees) which hampers nationwide screening due to
the financial barrier. The rate of uptake in private screening and information on the epidemi-
ology of screened women are not available in Vietnam. It is not possible to perform the
national mammography screening program for all Vietnamese women since the age-adjusted
incidence rate is lower than that in other countries and the budget of the healthcare system is
very limited. Therefore, the aim of this study is to estimate: (a) the cost-effectiveness of mam-
mography screening among Vietnamese women; (b) the appropriate age category for the first
round of mammography screening among Vietnamese women.
Methods
Model structure and assumptions
The screening strategy under evaluation is that women over 45 years of age are being screened
by mammography. Four age groups were considered: 45–49, 50–54, 55–59, and 60–64 years. It
was assumed that 100% of the target population would participate in the screening program.
The impact of the participation rate on the cost-effectiveness of mammography screening was
evaluated ranging from a 100% participation rate to a 23.6% participation rate which was
derived from the national breast cancer screening program in Korea [22]. The costs and out-
comes of mammography screening were compared with: (1) no screening (base case); (2) a
combination of 5% private screening and 95% no screening; (3) a combination of 10% private
screening and 90% no screening. A decision analytical modeling approach was used to detect
patients with breast cancer (Fig 1). Women with an abnormal mammogram were taken for an
extra laboratory test to diagnose breast cancer and were determined by the stage of cancer:
stage I, stage II, stage III, stage IV or metastatic stage. We assumed that all breast cancer
patients underwent prompt and adequate treatment. Women with a determined stage of can-
cer entered a Markov model linked to the decision tree model (Fig 2).
Fig 1. Decision tree model.
https://doi.org/10.1371/journal.pone.0194996.g001
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Markov chain analysis was used to calculate costs and life years gained due to early detection
of breast cancer. Entering the Markov model depends on the stage patients are being diagnosed.
The five states in the Markov model are: remission (after treatment), local recurrence, distant
recurrence, death due to breast cancer, and death due to other causes. In each one-year cycle,
women can enter the remission state and remain there or make a transition to local recurrence,
distant recurrence, death due to breast cancer, or death due to other causes. Women in the local
recurrence state can remain in this state or make a transition to distant recurrence, death due to
breast cancer or death due to other causes. Finally, women in the distant recurrence (including
stage IV) can remain at the same state or make a transition to death due to breast cancer or
death due to other causes [23]. The Markov model was run with a lifelong time horizon.
Model input parameters
Epidemiological parameters. Key parameters are summarized in Table 1. All-cause mor-
tality probabilities by age were obtained from data published by the General Statistics Office of
Fig 2. Health states and transitions.
https://doi.org/10.1371/journal.pone.0194996.g002
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Vietnam [24]. We used age-specific breast cancer incidence figures from online data of the
International Agency for Research on Cancer [8]. Breast cancer stage distributions in the non-
screened group were derived from a Vietnamese published article [25] while stage distribu-
tions in the screened group were obtained from the Chinese article of Wong et al. [17] as these
parameter estimates were not available in Vietnam. Ductal carcinoma in situ (DCIS) was
excluded from the model since epidemiological parameters related to DCIS were not recorded
in Vietnam. Due to the lack of data, it was assumed that stage distributions in the screened
group and the non-screened group were the same for each age group. We applied transition
probabilities between health states in the Markov model from a Canadian study [23]. It was
also assumed that transition probabilities between health states for the 60–64 age group were
the same as that for the 50–59 age group. The survival probability of patients with stage IV
breast cancer was estimated from a Vietnamese study [26] and was used to recalculate transi-
tion probabilities between health states in the Markov chain for scenario analyses (S1 Table).
Sensitivity and specificity of mammography screening. Due to the lack of data about
the accuracy of mammography screening in Vietnamese women, the sensitivity and specificity
of mammography screening programs were derived from a Japanese study [27].
Costs. The study was conducted from the viewpoint of the healthcare payer. Direct non-
medical costs and indirect costs (like productivity losses) were not included in this study. The
costs of tests were derived from a list of the Vietnamese Ministry of Health [28] and converted
to the US dollar (US$ 1 = VND 22,330). In Vietnam, there are main laboratory tests to diag-
nose breast cancer, including tumor biopsy, cytological tests, ultrasound, and CA15.3 [26]. In
this model, we assumed that among women with an abnormal mammogram, 50% required
biopsy and 50% required cytological testing. Treatment costs were obtained from a previously
published article of Nguyen Hoang Lan et al. [26]. These costs were adjusted to the year 2016
based on the Vietnamese Consumer Price Index [29] and included the initial treatment costs
and follow-up costs. It was assumed that treatment costs were the same for each age group and
the follow-up costs were the same for each cycle in the Markov model.
Outcomes
The model outcomes were: life year gained and total costs. The comparative performance of
the strategies was measured by using an Increment Cost Effectiveness Ratio (ICER) and/or an
Incremental Net Monetary Benefit (INMB). The ICER is defined as the difference in the total
costs between the new screening program and the no screening alternative, divided by the dif-
ference in the effectiveness between these two options. The Net Monetary Benefit measures
both cost and health outcome in terms of monetary value. Therefore, the INMB is calculated
as the difference in effectiveness between both alternatives multiplied by a given willingness-
to-pay threshold for a unit of effect gained, and then the difference in cost between both alter-
natives is subtracted from it [30]. The mammography screening is considered cost-effective if
the ICER was less than 3 times the GDP per capita according to the WHO recommendation
[31]. Both future health effects and costs were discounted at an annual rate of 3%. All analyses
were conducted using the TreeAge Pro 2016 software.
Uncertainty analyses
To check the robustness of our results, we conducted one-way sensitivity analyses presented
through a Tornado diagram. The parameters included in the one-way sensitivity analyses were
as follows: discount rate, initial treatment cost, follow-up cost, mammography sensitivity,
mammography specificity, and transition probabilities for the health states. Based on the litera-
ture, we determined a range of plausible values for the parameters in the model. In cases in
Cost-effectiveness of mammography screening
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Table 1. Complete model input.
Parameter Value Distribution Reference
Epidemiology
All-cause mortality: age distribution Invariant Vietnam [24]
45–49 0.0037
50–54 0.0058
55–59 0.0094
60–64 0.0159
65–69 0.0271
70–74 0.0452
75–79 0.0680
80+ 0.1129
Breast cancer incidence: age group Betaa Vietnam [8]
45–49 0.000689
50–54 0.000829
55–59 0.000818
60–64 0.000685
Breast cancer stage distribution: screened Dirichletb China [17]
Stage I 0.521
Stage II 0.382
Stage III 0.057
Stage IV 0.041
Breast cancer stage distribution: non-screened Dirichletb Vietnam [25]
Stage I 0.1118
Stage II 0.6118
Stage III 0.1941
Stage IV 0.0823
Stage progression transition probabilities Invariant Canada [23]
Age group 45–49
Stage I
Remission to Local recurrence 0.01
Remission to Distant recurrence 0.000016
Local recurrence to Distant recurrence 0.062
Local recurrence to breast cancer death 0.013
Distant recurrence to breast cancer death 0.555
Stage II&III
Remission to Local recurrence 0.018
Remission to Distant recurrence 0.024
Local recurrence to Distant recurrence 0.165
Distant recurrence to breast cancer death 0.386
Stage IV
Distant recurrence to breast cancer death 0.386
Age group 50–59
Stage I
Remission to Local recurrence 0.009
Remission to Distant recurrence 0.000025
Local recurrence to Distant recurrence 0.052
Distant recurrence to breast cancer death 0.137
Stage II&III
Remission to Local recurrence 0.016
Remission to Distant recurrence 0.105
Local recurrence to Distant recurrence 0.13
Distant recurrence to breast cancer death 0.423
Stage IV
Distant recurrence to breast cancer death 0.423
Survival probability of patients in stage IV 0.50 Invariant Vietnam [26]
(Continued)
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which ranges could not be found from the previously published documents, the range of values
that was used ±25% of the base-case as a conservative estimate (Table 2).
A probabilistic sensitivity analysis was performed to examine parameter uncertainty using
second order Monte Carlo simulation with 10,000 iterations. In conducting a probabilistic sen-
sitivity analysis, the distribution of each parameter was defined based on literature (Table 1).
Table 1. (Continued)
Parameter Value Distribution Reference
Mammography test
Sensitivity:age group Betac Japan [27]
45–49 0.714
50–59 0.858
60–64 0.872
Specificity: age group Betac
45–49 0.886
50–59 0.907
60–64 0.931
Cost (US$)
Mammography test 8.15 Invariant Vietnam [28]
Meeting with doctor 1.75 Invariant
Cost of further testing Invariant
Biopsy 6.45
Cytological test 4.66
Treatment costs Vietnam [26]
Initial treatment cost Gammad
Stage I 160.00
Stage II 458.48
Stage III 850.45
Stage IV 668.70
Follow-up cost 88.57 Gammad
a Parameters of the Beta distribution were derived from the number of cancer cases relative to the population by age groups.
b Parameter means of the distribution were equivalent to the sample size in each stage. Dirichlet was [1241;911;135;97] in the screened group and Dirichlet was
[106;580;184;78] in the non-screened groups.
c Parameters of the Beta distribution were derived from the number of cases having a positive result, a negative result, cancer, and no cancer.
 Costs were adjusted by the Vietnamese Consumer Price Index to the year 2016.
d The standard deviations for the initial treatment costs of stage I, II III and IV were US$190.76,US$546.64,US$1013.98, US$960.05, respectively. The standard deviation for
costs of follow-up care was US$66.47.
https://doi.org/10.1371/journal.pone.0194996.t001
Table 2. Parameters and value ranges used for one-way sensitivity analysis.
Parameter Low value High value
Mammography sensitivity 75% of base-case value 125% of base-case value
Mammography specificity 75% of base-case value 125% of base-case value
Transition rate from distant recurrence to cancer death 50% of base-case value 150% of base-case value
Transition rate from local recurrence to distant recurrence 50% of base-case value 150% of base-case value
Initial treatment cost 75% of base-case value 125% of base-case value
Follow-up cost 75% of base-case value 125% of base-case value
Discount rate 0% 6%
https://doi.org/10.1371/journal.pone.0194996.t002
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This analysis used the cost-effectiveness ceiling threshold (the willingness-to-pay threshold for
a life year gained) of three times GDP per capita. The Vietnamese GDP per capita in 2015 was
US$2,110.90 and the ceiling threshold, therefore, was US$6,332.70 per life year gained [32].
Ethics consideration
The Ethics Committee approval was not required for this cost-effectiveness study as model
parameters in this study were obtained from previously published data.
Results
Table 3 shows the estimated average total costs and average total life years gained per 100,000
women under different screening strategies. Among the screening policies that were assessed,
the first round of mammography screening in the 50–54 age group had the lowest ICER (US
$3,647.06 per life year gained) and highest INMB (US$775,674). Mammography screening for
women aged 55–59 years was estimated to gain 289 life years per 100,000 women and resulted
in an ICER of US$4,405.44 when compared to no screening. According to the INMB decision
rule (INMB>0), screening for the 45–49 age group and the 60–64 age group could not be con-
sidered cost-effective since INMBs were negative.
Furthermore, the impact of opportunistic screening and the participation rate on the cost-
effectiveness of mammography screening were explored since the rate of uptake in private
screening and the participation rate in mammography were not available in Vietnam. The
results showed that changing the percentage of individual screening from 0% to 10% had a
minor effect on the cost-effectiveness of mammography screening (Table 4). In fact, the INMB
turned out to be insensitive for changes in all screening policies: 100% no screening, 95% no
screening + 5% individual screening and 90% no screening + 10% individual screening. How-
ever, changing the participation rate from 100% to 23.6% had a high impact on the INMBs of
all age groups and mammography screening in the 50–54 age group, as well as the 55–59 age
group, was considered cost-effective with an INMB of US$183,059 and US$108,337,
respectively.
Due to the lack of Vietnamese data concerning transition probabilities between health states
in the Markov model, parameters from a Canadian study were used. The average total cost,
average total life years gained, the ICER and the INMB were analyzed by substitution of the
survival rate of stage IV in Vietnam for that of the parameters in Canada and recalculation of
Table 3. Costs and effects for comparison of screening strategies for 100,000 Vietnamese women.
Strategy Cost (US$) Life year gained ICER (US$)
per patient
INMB (US$)
Women aged 45–49 years
No screening 115,603 100,520
Mammography screening 1,169,942 100,640 8,782.70 -294,117
Women aged 50–54 years
No screening 104,134 100,096
Mammography screening 1,157,487 100,385 3,647.06 775,674
Women aged 55–59 years
No screening 99,351 99,689
Mammography screening 1,148,683 99,928 4,405.44 459,055
Women aged 60–64 years
No screening 79,603 98,897
Mammography screening 1,110,692 99,060 6,335.84 -512
https://doi.org/10.1371/journal.pone.0194996.t003
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transition probability parameters (Table 5). All ICERs of screening policies were lower than
their counterparts in the base case. However, screening for the 45–49 age group was not con-
sidered to be cost-effective regarding the threshold of US$6332.70 since the ICER in this group
was US$7,680.08. With these adjusted transition probability parameters, the ICER of mam-
mography screening for women aged 60–64 reduced from US$6,335.84 to US$5,799.90 and
was considered cost-effective.
Sensitivity analyses
To test the impact of certain parameters on the ICERs, one-way sensitivity analyses were con-
ducted for four screening policies. The eight parameters had an impact on the ICERs presented
in Fig 3. The ICERs were most sensitive to the ‘discount rate’ in the four screening policies.
‘Mammography sensitivity’ had the second-highest impact on the ICERs in the three age
groups: 45–49, 50–54, and 55–59 while ‘transition probability from remission to distant recur-
rence in stage II’ ranked the second among the parameters having a high effect on the ICER in
the 60–64 age group.
We performed a probabilistic sensitivity analysis to test the robustness of the model. Fig 4
shows cost-effectiveness acceptability curves of four strategies based on different ceiling
thresholds (Fig 4). Both screening for the 50–54 age group and the 55–59 age group would be
cost-effective compared to no screening at the ceiling threshold of US$6,332.70 per life year
gained. Compared to no screening for women aged 60–64, screening had a lower probability
Table 4. INMBs for comparison of changing the percentage of individual screening and the participation rate.
Group INMB (US$) of base
case
INMB (US$) of Screening vs. INMB (US$) of 23.6% screening vs. no
screening95% no screening+ 5% individual
screening
90% no screening+ 10% individual
screening
45–49
years
-294,117 -279,465 -264,815 -69,412
50–54
years
775,674 736,811 697,948 183,059
55–59
years
459,055 436,289 413,244 108,337
60–64
years
-512 -486 -460 -121
https://doi.org/10.1371/journal.pone.0194996.t004
Table 5. Costs and effects of screening policies when using adjusted transition probability parameters.
Strategy Cost (US$) Life year gained ICER (US$) INMB (US$)
Women aged 45–49 years
No screening 107,665 100,430
Mammography screening 1,163,548 100,568 7,680.08 -185,243
Women aged 50–54 years
No screening 98,241 100,030
Mammography screening 1,153,423 100,339 3,409.65 904,592
Women aged 55–59 years
No screening 94,066 99,630
Mammography screening 1,145,132 99,887 4,077.55 581,306
Women aged 60–64 years
No screening 75,724 98,853
Mammography screening 1,108,165 99,031 5,799.90 94,843
https://doi.org/10.1371/journal.pone.0194996.t005
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Fig 3. Impact of the parameters on the ICERs. D_R means discount rate; Dist_to_death_II: transition probability from distant
recurrence to death in stage II; Dist_to_death_IV: transition probability from distant recurrence to death in stage IV; Local_to_dist_II:
transition probability from local recurrence to distant recurrence in stage IV; R_to_dist_II: transition probability from remission to
distant recurrence in stage II; R_to_local_I: transition probability from remission to local recurrence in stage I; R_to_local_II: transition
probability from remission to local recurrence in stage II; Sensitivity: sensitivity of mammography; Specificity: specificity of
mammography.
https://doi.org/10.1371/journal.pone.0194996.g003
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of being cost-effective at the ceiling threshold since the screening program turned out to be
cost-effective in only 46.32% of cases. Fig 4 illustrates that 0% of cases were cost-effective at the
threshold if women aged 45–49 were screened.
Discussion
Low-cost screening approaches, such as clinical breast examination, could be implemented in
limited resource settings as the WHO recommends. Presently, there are some studies regard-
ing clinical breast examination as a method of breast cancer screening in Vietnam [33, 34].
However, these publications were cross-sectional studies with a small number of subjects and
did not provide the necessary information on parameters such as sensitivity, specificity of clin-
ical breast examination, and stage-specific diagnosis. So far, the only breast cancer screening
Fig 4. Cost-effectiveness acceptability curves for screening policies.
https://doi.org/10.1371/journal.pone.0194996.g004
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method that has been proven to be effective by early detection is mammography screening [2].
Accordingly, we analyzed the cost-effectiveness of mammography screening as compared to
no screening in Vietnamese women.
Although mammography screening for early detection of breast cancer has been adopted in
many Western countries, there are no data related to the effectiveness of mammography screen-
ing in Vietnam. As a result, we used parameters of breast cancer which were available in Vietnam
and used other parameters from other countries to analyze the cost-effectiveness of mammogra-
phy screening in Vietnamese women. Our results demonstrated that a single screening in the
50–54 age group, as well as the 55–59 age group, was cost-effective at the given ceiling threshold
of US$6,332.7, while screening for women aged 45–49 years and women aged 60–64 years were
not considered cost-effective. The reasons for this were that the incidence rate of breast cancer in
these groups is lower than that of the other groups [8] and the mammography sensitivity in
women in their 40s is relatively lower than for the older age groups [27, 35]. In addition, results
from randomized trials showed no significant effect on breast cancer mortality in women
between 40–49 years of age that were offered screening [36].
We also performed the cost-effectiveness of mammography screening in the second round
for four specific age groups and only screening in women aged 50–54 years was considered
cost-effective with an ICER of US$5,090.83 per life year gained (See S2 Table). This implies
that increasing the screening frequencies for women aged 45–64 years will increase life years
gained, but with decreasing cost-effectiveness of screening. More studies reported that cost per
life year gained was reduced as the screening interval increased [23, 37, 38]. Annual and bien-
nial mammography screening for women aged 45–64 years is not cost-effective because the
ceiling threshold is quite low in Vietnam. However, we estimated the cost-effectiveness of the
second round based on a lot of assumptions due to the lack of data, including similar stage dis-
tribution and transition probabilities as for the first round. It is expected that less aggressive
cancer is in the subsequent screening in clinical practice. Consequently, long follow-up studies
with a sufficient number of subjects should be conducted to estimate effectiveness of mam-
mography screening in Vietnamese women.
We also analyzed the impact of opportunistic screening and the participation rate on the
cost-effectiveness of mammography screening because of data scarcity in Vietnam. Our find-
ings showed that changing individual screening from 0% to 10% had a minor effect on the
cost-effectiveness of mammography screening while reducing the participation rate to 23.6%
had a high impact on the INMBs of all screening policies because of the large effect on total
costs. This was also found in the Canadian study [23].
The results of this study demonstrated that the discount rate, mammography sensitivity,
and the transition rate in health states had a substantial impact on the ICER in all four groups.
An important limitation in our study is the lack of data on mammography sensitivity for age-
specific groups of Vietnamese women and we, therefore, had to use data from a Japanese study
[27]. Factors such as age, screening interval, breast density, experience of trained professionals,
and medical equipment could affect the sensitivity of mammography screening which were
assumed to be similar to the Japanese condition.
Another limitation is that we applied transition probabilities between health states from a
Canadian study. However, we adjusted these transition probability parameters based on the
survival probability of stage IV of Vietnamese breast cancer patients which was lower than that
of Canada. The number of deaths from breast cancer as a percentage of incident cases in low-
income countries in 2008 was twice as high as that in high-income countries [39, 40]. The rea-
sons for these high mortality rates due to breast cancer are the lack of awareness of breast can-
cer patients, inadequate facilities for detection and diagnosis, and poor access to high-quality
treatment options in low and middle-income countries [40]. Breast cancer patients diagnosed
Cost-effectiveness of mammography screening
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at the late-stages of breast cancer had significantly higher initial treatment costs than that at
early-stages, while their survival probability was lower [26]. We found that all screening poli-
cies were more cost-effective when using adjusted transition probability parameters. There-
fore, early detection of breast cancer through the national screening program would probably
result in substantial improvements for the survival rate of patients in low- and middle-income
countries whilst the treatment of breast cancer is still limited.
As for Vietnam, there is no information available on the rate of tests used to diagnose after
screening. Therefore, only costlier invasive tests were included in the model to not underesti-
mate the total cost associated with screening for breast cancer. We acknowledge that more
non-invasive tests like ultrasound can also be part of the post-screening diagnosis pathway.
After breast cancer patients complete an initial treatment, they are often required to continue
treatment with follow-up care treatment and a range of methods is used in follow-up care
depending on characteristics of patients and disease status, such as breast cancer stage, local
recurrence and/or distant recurrence [26]. Due to the lack of such data, we assumed that cost
for follow-up care was the same for all stage-specific diagnosis and all age groups. However,
our one-way sensitivity analyses showed that the ICERs of all groups were insensitive to fol-
low-up cost as well as initial treatment cost. Wong et al. also found that treatment costs had a
minor impact on the ICER of breast cancer screening in Chinese women [17].
It has been well-known that the false-positive result is one of the harms of mammography
screening [41]. The risk of false-positive results is higher in young women [42]. It leads to
additional testing, such as biopsy, and ultrasound test, and is related to greater anxiety about
breast cancer or required psychological support [43]. Nevertheless, Maria et al. revealed that
women who experienced the false-positive mammogram still considered the false-positive
result as an acceptable risk [44]. This study was conducted from a healthcare perspective and
consequently, did not include non-medical costs or indirect costs outside healthcare in our
models. In addition to the harms of breast cancer screening, over-diagnosis which refers to a
tumor detected on screening and leads to be over-treated, is still remaining concern. DCIS–a
noninvasive form of breast cancer- is considered to be potential factor related to over-diagno-
sis. Due to the lack of information on DCIS in Vietnamese women and the fact that there is
currently no method of confirmation about the probability as well as timing from DCIS to
invasive cancer [45], we did not take DCIS into account in the models. As a consequence, the
cost-effectiveness of mammography screening could be overestimated and considered care-
fully before the national mammography program is introduced. At the individual level, bene-
fits and risks should be informed by health staffs and balanced information should be
considered as part of the personal decision-making process.
Although this study has limitations, the findings still provide the first piece of evidence
regarding the cost-effectiveness of mammography screening in Vietnamese women. Currently,
national programs and medical services covered by health insurance are not based on health-
economic assessment in Vietnam. However, the application of health-economic assessments
to medical services is considered to be mandatory when choosing health services. The results,
therefore, provide valuable information for decision-makers to choose cost-effective interven-
tions for breast cancer while the Vietnamese healthcare budget is limited. However, before
introducing national mammography screening, other factors should be taken into account to
make the implementation in Vietnamese circumstances successful. The results revealed that
the participation rate had a high impact on the effectiveness of national breast cancer screen-
ing. Hence, women’s values and preferences, such as the enhanced awareness of breast cancer,
preferred setting, time, and cost of travelling to a screening unit, cultural promotion for
screening, and changing beliefs of health service providers, should be part of the decision pro-
cess to encourage the higher uptake rate [46, 47]. Other assumptions, such as 100% adequate
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treatment in patients, should be considered when cost-effectiveness results were interpreted in
Vietnam. To reduce the mortality rate in breast cancer patients, the adequate treatment, along
with mammography screening, should be noticed.
Conclusions
Our analyses have illustrated that the first round of mammography screening for the 50–54
age group is the most cost-effective age-related screening scenario and furthermore, both
screening for the 50–54 age group and the 55–59 age group are cost-effective with the Viet-
namese ceiling threshold. For women aged 45–49 years, mammography screening is not cost-
effective since the incidence rate of breast cancer and the sensitivity of mammography in
women in this age group are lower than that of the other groups. The discount rate, mammog-
raphy sensitivity, and transition probability from remission to distant recurrence in stage II
have a large impact on the ICER in all four age groups. Further studies should be conducted to
examine the effectiveness of mammography screening and provide epidemiological data on
breast cancer in Vietnamese women.
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